Literature DB >> 19362127

Endophenotypes in normal brain morphology and Alzheimer's disease: a review.

C Reitz1, R Mayeux.   

Abstract

Late-onset Alzheimer's disease is a common complex disorder of old age. Though these types of disorders can be highly heritable, they differ from single-gene (Mendelian) diseases in that their causes are often multifactorial with both genetic and environmental components. Genetic risk factors that have been firmly implicated in the cause are mutations in the amyloid precursor protein (APP), presenilin 1 (PSEN1) and presenilin 2 (PSEN2) genes, which are found in large multi-generational families with an autosomal dominant pattern of disease inheritance, the apolipoprotein E (APOE)epsilon4 allele and the sortilin-related receptor (SORL1) gene. Environmental factors that have been associated with late-onset Alzheimer's disease include depressive illness, various vascular risk factors, level of education, head trauma and estrogen replacement therapy. This complexity may help explain their high prevalence from an evolutionary perspective, but the etiologic complexity makes identification of disease-related genes much more difficult. The "endophenotype" approach is an alternative method for measuring phenotypic variation that may facilitate the identification of susceptibility genes for complexly inherited traits. The usefulness of endophenotypes in genetic analyses of normal brain morphology and, in particular for Alzheimer's disease will be reviewed as will the implications of these findings for models of disease causation. Given that the pathways from genotypes to end-stage phenotypes are circuitous at best, identifying endophenotypes more proximal to the effects of genetic variation may expedite the attempts to link genetic variants to disorders.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19362127      PMCID: PMC2812814          DOI: 10.1016/j.neuroscience.2009.04.006

Source DB:  PubMed          Journal:  Neuroscience        ISSN: 0306-4522            Impact factor:   3.590


  125 in total

1.  A polymorphism in CALHM1 influences Ca2+ homeostasis, Abeta levels, and Alzheimer's disease risk.

Authors:  Ute Dreses-Werringloer; Jean-Charles Lambert; Valérie Vingtdeux; Haitian Zhao; Horia Vais; Adam Siebert; Ankit Jain; Jeremy Koppel; Anne Rovelet-Lecrux; Didier Hannequin; Florence Pasquier; Daniela Galimberti; Elio Scarpini; David Mann; Corinne Lendon; Dominique Campion; Philippe Amouyel; Peter Davies; J Kevin Foskett; Fabien Campagne; Philippe Marambaud
Journal:  Cell       Date:  2008-06-27       Impact factor: 41.582

2.  Epidemiological, clinical, and neuropathological study of apolipoprotein E genotype in Alzheimer's disease.

Authors:  B T Hyman; T Gomez-Isla; G W Rebeck; M Briggs; H Chung; H L West; S Greenberg; S Mui; S Nichols; R Wallace; J H Growdon
Journal:  Ann N Y Acad Sci       Date:  1996-12-16       Impact factor: 5.691

3.  Longitudinal memory performance during normal aging: twin association models of APOE and other Alzheimer candidate genes.

Authors:  Chandra A Reynolds; Jonathan A Prince; Lars Feuk; Anthony J Brookes; Margaret Gatz; Nancy L Pedersen
Journal:  Behav Genet       Date:  2006-01-10       Impact factor: 2.805

4.  Memory performance and the apolipoprotein E polymorphism in a community sample of middle-aged adults.

Authors:  J D Flory; S B Manuck; R E Ferrell; C M Ryan; M F Muldoon
Journal:  Am J Med Genet       Date:  2000-12-04

5.  Three SNPs in the GSTO1, GSTO2 and PRSS11 genes on chromosome 10 are not associated with age-at-onset of Alzheimer's disease.

Authors:  Ayla Ozturk; Purnima P Desai; Ryan L Minster; Steven T Dekosky; M Ilyas Kamboh
Journal:  Neurobiol Aging       Date:  2004-12-18       Impact factor: 4.673

6.  Family-based association between Alzheimer's disease and variants in UBQLN1.

Authors:  Lars Bertram; Mikko Hiltunen; Michele Parkinson; Martin Ingelsson; Christoph Lange; Karunya Ramasamy; Kristina Mullin; Rashmi Menon; Andrew J Sampson; Monica Y Hsiao; Kathryn J Elliott; Gonül Velicelebi; Thomas Moscarillo; Bradley T Hyman; Steven L Wagner; K David Becker; Deborah Blacker; Rudolph E Tanzi
Journal:  N Engl J Med       Date:  2005-03-03       Impact factor: 91.245

7.  Possible association between SORL1 and Alzheimer disease? Reanalysing the data of Shibata et al.

Authors:  Joseph H Lee; Nobuto Shibata; Rong Cheng; Richard Mayeux
Journal:  Dement Geriatr Cogn Disord       Date:  2008-11-04       Impact factor: 2.959

8.  Clinical and pathological correlates of apolipoprotein E epsilon 4 in Alzheimer's disease.

Authors:  T Gomez-Isla; H L West; G W Rebeck; S D Harr; J H Growdon; J J Locascio; T T Perls; L A Lipsitz; B T Hyman
Journal:  Ann Neurol       Date:  1996-01       Impact factor: 10.422

9.  Clinical, pathological, and neurochemical changes in dementia: a subgroup with preserved mental status and numerous neocortical plaques.

Authors:  R Katzman; R Terry; R DeTeresa; T Brown; P Davies; P Fuld; X Renbing; A Peck
Journal:  Ann Neurol       Date:  1988-02       Impact factor: 10.422

10.  Common genetic variation within the low-density lipoprotein receptor-related protein 6 and late-onset Alzheimer's disease.

Authors:  Giancarlo V De Ferrari; Andreas Papassotiropoulos; Travis Biechele; Fabienne Wavrant De-Vrieze; Miguel E Avila; Michael B Major; Amanda Myers; Katia Sáez; Juan P Henríquez; Alice Zhao; M Axel Wollmer; Roger M Nitsch; Christoph Hock; Chris M Morris; John Hardy; Randall T Moon
Journal:  Proc Natl Acad Sci U S A       Date:  2007-05-21       Impact factor: 11.205

View more
  21 in total

1.  From the genome to the phenome and back: linking genes with human brain function and structure using genetically informed neuroimaging.

Authors:  H R Siebner; J H Callicott; T Sommer; V S Mattay
Journal:  Neuroscience       Date:  2009-09-12       Impact factor: 3.590

2.  TOMM40 poly-T repeat lengths, age of onset and psychosis risk in Alzheimer disease.

Authors:  Su Hee Chu; Kathryn Roeder; Robert E Ferrell; Bernie Devlin; Mary Ann A DeMichele-Sweet; M Ilyas Kamboh; Oscar L Lopez; Robert A Sweet
Journal:  Neurobiol Aging       Date:  2011-08-05       Impact factor: 4.673

Review 3.  Mitochondrial DNA deletions in Alzheimer's brains: a review.

Authors:  Nicole R Phillips; James W Simpkins; Rhonda K Roby
Journal:  Alzheimers Dement       Date:  2013-07-11       Impact factor: 21.566

4.  COMT Val158Met Genotype and Individual Differences in Executive Function in Healthy Adults.

Authors:  Heather A Wishart; Robert M Roth; Andrew J Saykin; C Harker Rhodes; Gregory J Tsongalis; Kristine A Pattin; Jason H Moore; Thomas W McAllister
Journal:  J Int Neuropsychol Soc       Date:  2010-12-10       Impact factor: 2.892

5.  Impact of SORL1 single nucleotide polymorphisms on Alzheimer's disease cerebrospinal fluid markers.

Authors:  Panagiotis Alexopoulos; Liang-Hao Guo; Martina Kratzer; Christine Westerteicher; Alexander Kurz; Robert Perneczky
Journal:  Dement Geriatr Cogn Disord       Date:  2011-10-13       Impact factor: 2.959

6.  Attentional performance, impulsivity, and related neurotransmitter systems in apoE2, apoE3, and apoE4 female transgenic mice.

Authors:  Ingrid Reverte; Fiona Peris-Sampedro; Pia Basaure; Leticia Campa; Cristina Suñol; Margarita Moreno; José Luis Domingo; Maria Teresa Colomina
Journal:  Psychopharmacology (Berl)       Date:  2016-01       Impact factor: 4.530

Review 7.  Imaging Endophenotypes of Stroke as a Target for Genetic Studies.

Authors:  Xueqiu Jian; Myriam Fornage
Journal:  Stroke       Date:  2018-05-14       Impact factor: 7.914

8.  A new role for endophenotypes in the GWAS era: functional characterization of risk variants.

Authors:  Mei-Hua Hall; Jordan W Smoller
Journal:  Harv Rev Psychiatry       Date:  2010 Jan-Feb       Impact factor: 3.732

Review 9.  Early Life Stress and Epigenetics in Late-onset Alzheimer's Dementia: A Systematic Review.

Authors:  Erwin Lemche
Journal:  Curr Genomics       Date:  2018-11       Impact factor: 2.236

Review 10.  The paradox of syndromic diversity in Alzheimer disease.

Authors:  Jason D Warren; Phillip D Fletcher; Hannah L Golden
Journal:  Nat Rev Neurol       Date:  2012-07-17       Impact factor: 42.937

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.